NAMS  NewAmsterdam Pharma Company N.V.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events. It also develops obicetrapib for Alzheimer's disease. The company was founded in 2019 and is based in Naarden, the Netherlands.